Articles

Back to Articles

Trelagliptin Succinate - A Once-a-Week Treatment for Type 2 Diabetes - Coming Soon !

(Pub. 1st November 2012)

Cases of Diabetes, particularly type 2 Diabetes, have skyrocketed worldwide. According to researchers at the Hebrew University of Jerusalem in Israel, an estimated half a million people in Israel have been diagnosed with diabetes as of early 2012. In the United States the figures are even more startling, with 20.8 million adults and children suffering from this disease. In both Israel and the United States, the majority of cases of Diabetes are of the type 2 origin, roughly 90 percent of these patients.

With medical analysts predicting a massive climb in cases of type 2 diabetes worldwide over the next several decades, and the World Health Organization stating that there will be 366 million people worldwide affected by diabetes by 2030, innovative and efficacious treatments are in high demand. The advent of Trelagliptin Succinate, a novel once weekly medication for patients with type 2 Diabetes is now the focus of clinical trials. Sponsored by Takeda, Trelagliptin Succinate is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor. 

Currently all available DPP-4 inhibitors are offered as a once-daily dose, so the unique once a week dosing of Trelagliptin is not only innovative, but it is also exciting! The alternative for patients to experience an easy once a week dose versus having to remember a daily dose is enticing to many diabetics.  In addition to the ease of use, Trelagliptin has the potential to greatly improve treatment compliance.

 Phase III clinical trials commenced in September 2011, with Takeda recruiting approximately 600 patients with type 2 Diabetes for a 52 week, open-label study in Japan. The study is estimated to be complete by the second half of 2013. Earlier studies of Trelagliptin were completed globally in 2008. One study compared Trelagliptin to both a placebo, and to Sitagliptin Phosphate, which is currently marketed as Januvia.  The doses of Trelagliptin were 3.125 mg, 12.5 mg, 50 mg and 100 mg. While exact results have yet to be revealed, the study goals appear to be met, which were a decrease in the HbA(1c) levels of patients at the 12 week mark. The latest recruiting suggests that the prior studies have been successful. 

Furthermore, it is interesting to note that Trelagliptin is the only ‘gliptin’ to have already passed the crucial cardiovascular safety tests that underscore the very therapeutic advantage compared to other ‘gliptins’. These cardiovascular safety tests are demanded by the FDA, supporting further US registration for Trelagliptin Succinate. Most of the other DPP-4 inhibitors (all ‘gliptins’), owing to their mechanism of action, are known to cause cardiovascular complications.

 Researchers are currently looking at both the solutions, and the precursors to type 2 Diabetes. Environment and the developed world are proving to be impressive catalysts in the increase of type 2 patients. For example, the population of Ethiopian Jews, who are now living in Israel, used to reside in Africa, and diabetes was non-existent for this group of people.  A staggering 17 percent of the 75,000 Ethiopian Israelis now have diabetes. The diet, lifestyle changes, environment and stress are all possible contributors, leading scientists to attempt to isolate immigrant groups worldwide who may be at risk for type 2 Diabetes. Medications like Trelagliptin and Alogliptin are currently being examined as optimal anti-diabetic treatments in the DPP-4 inhibitor class. While Trelagliptin has the same mechanism of action as Alogliptin, the once-weekly treatment, (versus the once-daily oral therapy for Alogliptin) makes Trelagliptin an effectively simpler option for patients in the future. Therefore it is our belief that Trelagliptin Succinate will eventually supersede all other ‘gliptins’, due to it’s main advantages of the once-weekly treatment, it’s superior efficacy and that Trelagliptin has passed the cardiovascular safety tests that are demanded by the FDA and in future by other global regulatory authorities.

YES Pharma is proud to be a leading supply source for Trelagliptin Succinate (CAS#: 1029877-94-8) to several global pharmaceutical companies and academic research institutes, while recognizing that we play a significant part in the battle against type II Diabetes. The Trelagliptin Succinate that YES Pharma supplies is intended for laboratory R&D use only.

References:

Takeda Pharmaceuticals
World Health Organization
JewishJournal.com
Defeat diabetes: visiting Ethiopian Jews learn to deal with diabetes patients. Defeat Diabetes Association. February 13, 2011.
 

  • Products covered by valid patents are not offered or supplied for commercial use.
  • Products currently covered by valid US patents are offered only for laboratory R&D use in accordance
    with 35 USC 271(e)+A13(1).
  • Any patent infringement and resulting liability is solely at buyer risk.

 

 

Dun and Bradstreet